PHASE 1
Determination of prevalence of dosing inadequacy and DRPs rate

22 community pharmacies
N = 566 patients screened
1922 drugs with renal restrictions

N = 263 patients with renal impairment (FGR or ClCr<60 mL/min/1.73m²)
1049 drugs with renal restrictions

176 patients were randomly selected to be used a comparator group for Phase 2
700 drugs with renal restrictions

CONTROL GROUP

PHASE 2
Determination of effectiveness of community pharmacist intervention

18 community pharmacies
N = 440 patients screened
1392 drugs with renal restrictions

EXCLUDED N = 303
N = 300 without renal impairment
N = 3 not taking drugs with renal restrictions

N = 178 with renal impairment (FGR or ClCr<60 mL/min/1.73m²)
614 drugs with renal restrictions

INTERVENTION GROUP

EXCLUDED N = 262
N = 258 without renal impairment
N = 4 not taking drugs with renal restrictions